Could a glaucoma eye drop also heal the cornea?
NCT ID NCT06960629
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study tests whether a combination eye drop (netarsudil/latanoprost) can improve vision and reduce corneal thickness in people with glaucoma and a condition called pseudophakic bullous keratopathy, where the cornea swells after cataract surgery. Half of the 50 participants receive the active drops once daily for three months, while the other half receive placebo artificial tears. Researchers measure visual acuity and corneal thickness every two weeks to see if the drug helps.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Netarsudil/latanoprost eye drops
What this could lead to
If effective, these eye drops could offer a non-surgical way to improve vision and reduce corneal swelling in patients with glaucoma and pseudophakic bullous keratopathy.
What could go wrong
This is a small, early-stage trial with only 50 participants. The treatment may not prove better than placebo, and eye drops can cause irritation or redness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLAUCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Dubrava
Zagreb, Croatia, 10000, Croatia